Skip to main content

Delaet Ingrid's Form 4 filing

Neurocrine Biosciences Inc (NBIX) · filed Mar 25, 2024

Accession no.
0000914475-24-000098
Filed
Mar 25, 2024
Trade date
Mar 21, 2024
Filing delay
4 days
Rule 10b5-1 plan
Checked

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $725.3K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Delaet IngridCIK 0001965808Officer (Chief Regulatory Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 21, 2024Common StockMOption exerciseAcquired+5,000$103.52+$517,60012,507Direct
Mar 21, 2024Common StockSSaleDisposed−5,000$145.06F2−$725,3007,507Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 21, 2024Common StockMOption exerciseDisposed−5,000$103.52−$517,60027,049Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Transactions at prices ranging from $145.00 to $145.24. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)